Israel Active

I reported previously on Israel’s Tytocare and its handheld diagnostic device.  The device has been enhanced and Tytocare has received US FDA clearance for its digital stethoscope that performs enhanced remote diagnosis of a patient without the physician being present.

Israel’s Granalix has launched GranaGard - a food supplement that prevented neurodegeneration diseases in clinical tests.  GranaGard, is a submicron (nanodrops) Pomegranate Seed Oil emulsion with 80% Punicic acid - one of the strongest natural antioxidants.

Israel’s CephX provides dental and orthodontic practitioners with Cephalometric X-Ray analyses, image archiving and patient record management – all securely maintained on the cloud (rather in the dental surgery).  

Israel’s ImmunArray is developing blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases, including brain injury. It has just received a major investment from America’s Quanterix Corporation.

Israel’s Neurim is conducting a Phase 2 trial of its Piromelatine treatment, for Alzheimer’s disease (AD). The 26-week trial will compare once-daily oral doses of Piromelatine to placebo in approximately 500 patients diagnosed with mild AD.

I highlighted Teva’s SD-809 (deutetrabenazine) treatment for tardive dyskinesia. The disease causes uncontrollable movements in around 500,000 US patients. The second Phase III trial of the treatment produced statistically significant results.

Israel’s CollPlant has been awarded the EU CE Mark for VergenixSTR, a soft tissue repair matrix for the treatment of tendinopathy (tendon injury or disease and associated pain).  VergenixSTR is based on CollPlant’s proprietary plant-based collagen technology.

United Nations peacekeeping forces are to participate in a special emergency field medicine seminar headed by the Israeli military and local medical professionals. They will learn the unique methods Israel uses to deal with cases involving emergency medicine on the ground.

I reported previously on the Hebrew University scientists’ peptide treatment for HIV that uses multiple copies of the virus to make it self-destruct. It has now been tested on the blood from AIDS patients and has similar results to earlier clinical trials.

Israel’s Therapix Biosciences has developed a unique tablet for sublingual (under the tongue) administration of THC. A clinical trial of this tablet is anticipated to commence early 2017 for treatment of impairments in cognitive functioning, including early stages of Alzheimer's disease.